Name | Etripamil |
Synonyms | MSP-2017 Etripamil (-)-MSP-2017 Benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl ester |
CAS | 1593673-23-4 |
Molecular Formula | C27H36N2O4 |
Molar Mass | 452.59 |
Density | 1.079±0.06 g/cm3(Predicted) |
Boling Point | 593.8±50.0 °C(Predicted) |
Solubility | Soluble in DMSO |
pKa | 8.92±0.50(Predicted) |
Storage Condition | -20℃ |
Use | Etripamil is a calcium channel blocker. Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are several medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension. |
Reference Show more | [1]. Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497.[2]. Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.21 ml | 11.048 ml | 22.095 ml |
5 mM | 0.442 ml | 2.21 ml | 4.419 ml |
10 mM | 0.221 ml | 1.105 ml | 2.21 ml |
5 mM | 0.044 ml | 0.221 ml | 0.442 ml |